ACCU-BREAK PHARMACEUTICALS, INC & STRIDES ARCOLAB LIMITED ENTER INTO A WORLDWIDE JOINT VENTURE TO DEVELOP GENERIC PHARMACEUTICALS USING ACCU-BREAK TECHNOLOGIES

June 6, 2006 ACCU-BREAK Pharmaceuticals, Inc. and Strides Arcolab Limited, one of India's largest manufacturers and exporters of pharmaceutical products, today announced the signing of a definitive agreement to set up a world-wide Joint Venture Company (JVC) to develop generic products using the patent pending ACCU-BREAKTM technologies. This will be accomplished through a NEWCO to be called ACCU-STRIDES, a 50:50 JVC. It is anticipated that the JVC will outsource from Strides an exclusive product pipeline of generic and ANDA products in finished dosage forms. It is also anticipated that the JVC will outsource from ACCU-BREAK Pharmaceuticals sales, marketing and distribution capabilities for the North American markets while Strides will provide sales, marketing and distribution capabilities for the rest of the world. The product dossiers developed for the JVC by Strides will be owned exclusively by JVC. ACCU-BREAK tablets are designed for maximal dose accuracy when split, as well as for ease of breaking and to provide an optimal dosage for the millions of patients who split the tablets. Currently, Strides has a total of fourteen manufacturing plants worldwide including an FDA approved plant in Bangalore, India where the ACCU-BREAK products will be manufactured. It is expected that the products using the ACCU-BREAK technologies will be developed for regulatory submission world wide beginning in FY 2007. Lawrence Solomon, M.D., Chairman & CEO of ACCU-BREAK Pharmaceuticals, Inc. stated, “ACCU-BREAK tablets are “Simply Better” TM because they are “Made to be Broken” TM or taken intact. ACCU-BREAK products are designed to provide an unprecedented degree of dosage flexibility by allowing easy and very accurate tablet breaking when a partial dose is desired. ACCU-BREAK products will have important quality advantages over standard products and in addition will allow for cost savings”. Arun Kumar, Vice-Chairman and Group CEO of Strides stated, "The ACCU-BREAK – Strides JVC is a true reflection of the “Strides Value” partnership model. Using our niche manufacturing and product development skill sets, Strides will ramp-up the product pipeline to leverage various ACCU-BREAK technologies to create a worldwide specialty generic pharmaceutical company. We will work towards creating critical mass for the JVC and significant value to all stakeholders."

About ACCU-BREAK Pharmaceuticals, Inc. ACCU-BREAK Pharmaceuticals, Inc. is a privately held pharmaceutical company engaged in bio-equivalent product development utilizing its patent pending ACCU-BREAK technologies. The Company also intends to make its technologies available for licensing. About Strides Arcolab Limited. Strides Arcolab Limited, listed on the Indian National Stock Exchange (STAR), has a global presence in more than 50 countries. The company has factories in India, USA, Poland, Italy, Brazil and Mexico. The Company supplies pharmaceuticals to a number of geographic locations including Latin America, Europe, South East Asia, Africa and Australia, amongst other markets. The Indian manufacturing facilities for the regulated markets are approved by all major regulatory bodies such as USFDA, MHRA, TGA and MCC. Additional information is available at the Company's website at www.stridesarco.com.

This press release contains “forward-looking statements”. You can identify these statements by the fact that they use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. All forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement related to product liability, patent protection, governmental investigations, and other legal proceedings; Accu-Break’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approvals or the timing or terms of such approvals; and any changes in business, political, and economic conditions. Strides Arcolab Limited disclaims any responsibility to update any forward-looking statements.

Contacts: Adfactors PR, Mumbai Tel : 022-2281 3565 Fax : 022 – 2281 3569 For ACCU-BREAK Pharmaceuticals, Inc. Elliot F. Hahn, Ph.D. President Tel: (954) 236-7351 Ext. 100

STRIDES COMPLETES ACQUISITION IN POLAND

18th May 2006 Today Strides Polska announced that they had completed the acquisition of the former ICN Valeant sterile manufacturing unit in Warsaw, Poland. The acquisition now releases Strides Polska to begin the expansion of its operations in Eastern Europe as part of Strides Global Network. Strides Arcolab already has a significant manufacturing position in North and South America, in addition to the plants in India. The addition of Strides Polska’s facility to its Global Network has now added to their European operations which started with the acquisition of the Italian pharmaceutical plant, Beltapharm, in 2006. Paul Moore, President Global Manufacturing, said “This addition further strengthens Strides presence in Europe and allows us to focus on developing the Polish operations into a strategic part of our manufacturing network, as well as allowing us to promote our products and services in the “New Europe”. The planned expansion will create a state-of-the-art sterile facility which will lead to increased production capabilities for the Strides group. Whilst focusing on the European markets, we intend to utilize the unit and its team to supply on a global basis, teaming up with our other plants worldwide. Our planned investments will increase present production capacity as well as introducing new sterile dose forms to the site.” The Strides Group stated that it intends to install additional and new capacity, in sterile dose form at the plant and the expansion is planned to allow Strides Polska to supply Global as well as European markets. The expansion is expected to lead to an enlargement of the workforce and Strides Polska is expecting this expansion phase to be completed by early 2007.
ABOUT STRIDES ARCOLAB LIMITED Strides is one of India’s largest exporters of branded generic pharmaceutical products. Strides manufactures pharmaceuticals formulations in various dosage forms, including capsules, tablets, liquid injectables and is one of the world’s top five manufacturers of softgel capsules. In addition, Strides undertakes contract research and the manufacturing of specialty chemicals for various multinational companies. Strides has a major presence in various developing countries such as Africa, Latin America and Asia as well as in developed markets such as the US, Canada and parts of Europe. Strides has 11 manufacturing plants spread across the US, Brazil, Mexico, Europe and India. This broad manufacturing network facilitates partnering with global organizations ranging from UNICEF and WHO-Global Drug Facility to European and American pharmaceutical multinationals and also private labelers and distribution chains. Strides has product registrations in over 37 countries around the world and has earned ISO 9001, ISO 14001 and GMP accreditations including USFDA. Strides employs approximately 1,300 people across the globe. Strides also has a marketing presence in over 50 countries. For further information, please contact Adfactors PR, Mumbai Tel : 022-2281 3565

Strides Arcolab records consolidated sales of Rs.1.39 billion and PBT of Rs. 168.48 million for Qtr I of its FY2006 registering a 34% and 43% growth in revenue and PBT respectively over similar period last year.